Glioblastoma: new therapeutic strategies to address cellular and genomic complexity

Xue Cai; Michael E. Sughrue

doi:10.18632/oncotarget.23476

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Glioblastoma: new therapeutic strategies to address cellular and genomic complexity

Xue Cai and Michael E. Sughrue _

PDF | HTML | How to cite

Oncotarget. 2018; 9:9540-9554. https://doi.org/10.18632/oncotarget.23476

Metrics: PDF 2098 views | HTML 4109 views | ?

Abstract

Xue Cai1 and Michael E. Sughrue1

1Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA

Correspondence to:

Michael E. Sughrue, email: [email protected]

Keywords: glioblastoma; molecular mechanisms; gene therapy; immunotherapy; CRISPR/Cas9 genome editing

Received: August 11, 2017 Accepted: December 08, 2017 Published: December 20, 2017

ABSTRACT

Glioblastoma (GBM) is the most invasive and devastating primary brain tumor with a median overall survival rate about 18 months with aggressive multimodality therapy. Its unique characteristics of heterogeneity, invasion, clonal populations maintaining stem cell-like cells and recurrence, have limited responses to a variety of therapeutic approaches, and have made GBM the most difficult brain cancer to treat. A great effort and progress has been made to reveal promising molecular mechanisms to target therapeutically. Especially with the emerging of new technologies, the mechanisms underlying the pathology of GBM are becoming more clear. The purpose of this review is to summarize the current knowledge of molecular mechanisms of GBM and highlight the novel strategies and concepts for the treatment of GBM.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23476

Publication Alerts

Reviews:

Glioblastoma: new therapeutic strategies to address cellular and genomic complexity

Abstract